Headlines about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medidata Solutions earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.1187472033589 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Medidata Solutions (NASDAQ MDSO) traded down $0.73 during mid-day trading on Wednesday, reaching $67.84. 341,099 shares of the company traded hands, compared to its average volume of 642,936. Medidata Solutions has a 52 week low of $54.91 and a 52 week high of $85.92. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $3,970.00, a PE ratio of 90.45, a P/E/G ratio of 3.56 and a beta of 1.55.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, February 8th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The company had revenue of $141.20 million for the quarter, compared to analysts’ expectations of $140.65 million. During the same quarter last year, the company posted $0.33 earnings per share. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. analysts predict that Medidata Solutions will post 0.97 EPS for the current year.
In other news, CEO Tarek Sherif sold 26,836 shares of Medidata Solutions stock in a transaction on Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $65.95, for a total transaction of $131,900.00. Following the transaction, the chief financial officer now owns 89,775 shares in the company, valued at approximately $5,920,661.25. The disclosure for this sale can be found here. Insiders sold 35,836 shares of company stock worth $2,494,989 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.
WARNING: This story was originally reported by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://baseballnewssource.com/2018/03/14/medidata-solutions-mdso-earning-somewhat-positive-media-coverage-report-shows/1927593.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.